Merck's earnings call showcased strong progress, particularly with the successful launch of KEYTRUDA and its expansion into new indications like non-small cell lung cancer. The company's solid financial performance, ahead-of-schedule cost reductions, and significant returns to shareholders indicate a positive near-term outlook. These factors suggest the stock is likely to see a positive impact in the short term.

[1]